The combination of ribavirin and pegylated interferon-α is considered the standard of care for HCV-2/3 genotypes. The immune system plays a key role in the achievement of a sustained virological response (SVR). Vitamin D seems to influence antiviral response in chronic hepatitis C and its pathway is controlled by polymorphic genes such as CYP27B1, CYP24A1 and VDR. In this study, we have investigated the correlation among the treatment outcomes and single nucleotide polymorphisms (SNPs) in the above-mentioned genes and IL28B genes.
Methods
A total of 112 HCV-2/3 patients treated with interferon plus ribavirin were retrospectively studied; allelic discrimination was performed by real-time PCR.
Results
CYP24A1rs2585428, IL28Brs12979860 and rs8099917 SNPs affected treatment failure and body mass index (BMI), Metavir score, IL28Brs8099917TT and CYP24A1rs2585428GG were the only factors able to predict it. SVR was predicted by Metavir score, HCV RNA at baseline and early virological response (EVR). IL28Brs12979860 SNP and HCV RNA were also related to rapid virological response. EVR was predicted by BMI, Metavir score and CYP24A1rs2585428 SNP. IL28Brs8099917TT and FokITT were relapse prediction factors.
Conclusions
In addition to non-genetic factors, SNPs in the vitamin D pathway seem to have a role in HCV-2/3 therapy outcomes. This study reveals the likely usefulness of pharmacogenetic-based ribavirin and interferon therapy to help identify patients for whom therapy could be successful or not, also considering new future expensive therapy options. To date, no similar data were published on these viral genotypes, but further studies in different and bigger cohorts are needed.
References
1.
HopeV.D., EramovaI., CapurroD., DonoghoeM.C.Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association.Epidemiol Infect2014; 142: 270–286.
HadziyannisS.J., SetteH.Jr., MorganT.R.Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.Ann Intern Med2004; 140: 346–355.
4.
GeD., FellayJ., ThompsonA.J.Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.Nature2009; 461: 399–401.
5.
ThimmeR., BukhJ., SpangenbergH.C.Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease.Proc Natl Acad Sci U S A2002; 99: 15661–15668.
6.
PoonA.H., GongL., Brasch-AndersenC.Very important pharmacogene summary for VDR.Pharmacogenet Genomics2012; 22: 758–763.
7.
StokesC.S., VolmerD.A., GrunhageF., LammertF.Vitamin D in chronic liver disease.Liver Int2013; 33: 338–352.
8.
ShahS.R., PatelK., MarcellinP.Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3.Clin Gastroenterol Hepatol2011; 9: 688–693.
9.
HuangC.F., DaiC.Y., YehM.L.Virological predictors of response to retreatment in hepatitis C genotype 2 infected patients.PLoS ONE2013; 8: e58882.
10.
JiaZ., DingY., TianS., NiuJ., JiangJ.Test of IL28B polymorphisms in chronic hepatitis C patients treated with PegIFN and ribavirin depends on HCV genotypes: results from a meta-analysis.PLoS ONE2012; 7: e45698.
11.
SarinS.K., KumarC.K.Treatment of patients with genotype 3 chronic hepatitis C–current and future therapies.Liver Int2012; 32Suppl 1: 141–145.
12.
MangiaA., MottolaL., SantoroR.Interleukin 28B polymorphisms as predictor of response in hepatitis C virus genotype 2 and 3 infected patients.World J Gastroenterol2013; 19: 8924–8928.
13.
García-MartínE., AgundezJ.A., MaestroM.L.Influence of vitamin D-related gene polymorphisms (CYP27B and VDR) on the response to interferon/ribavirin therapy in chronic hepatitis C.PLoS ONE2013; 8: e74764.
14.
D'AvolioA., CiancioA., SiccardiM.Negative predictive value of IL28B, SLC28A2 and CYP27B1 SNPs and low RBV plasma exposure for therapeutic response to PEG/IFN-RBV treatment.Ther Drug Monit2012; 34: 722–728.
15.
HoltS.K., KwonE.M., KoopmeinersJ.S.Vitamin D pathway gene variants and prostate cancer prognosis.Prostate2010; 70: 1448–1460.
